Clinical trials: Locally Advanced Malignant Neoplasm
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Non Small Cell Lung Cancer (NSCLC)
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced…
- Trial name
- NCT00492206
- Testing
- Cetuximab
- Where
- 31 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Carcinoma, Non-Small-Cell Lung
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) <1.5 m2 and locally advanced or…
- Trial name
- NCT02300298
- Testing
- Nintedanib, Docetaxel
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Soft Tissue Sarcoma
TVEC and Preop Radiation for Sarcoma (4 ml Dose)
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy.
- Trial name
- NCT02453191
- Testing
- Talimogene Laherparepvec, Radiotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Iowa
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve…
- Trial name
- PEONY (NCT02586025)
- Testing
- FEC Chemotherapy, Surgery, Docetaxel
- Where
- 23 sites in China, South Korea and 2 more
- Volunteers
- 329 people
- Sponsor
- Hoffmann-La Roche
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
This is a randomized, controlled, double-blind, multicenter, phase III clinical study.
- Trial name
- NCT03849768
- Testing
- HS-10296, Gefitinib
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase II trial studies how well v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor MK2206 works in treating patients with previously treated colon or rectal cancer that has spread from the primary site to other…
- Conditions
- Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
- Trial name
- NCT01802320
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04527549
- Testing
- Dabrafenib mesylate, Hydroxychloroquine, Trametinib dimethyl sulfoxide
- Where
- 199 sites in United States
- Volunteers
- 5 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Carcinoma, Non-Small-Cell Lung
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable…
- Trial name
- PACIFIC-5 (NCT03706690)
- Testing
- Durvalumab
- Where
- 87 sites in China, Hong Kong and 8 more
- Volunteers
- 407 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
The intention of this trial is to determine the maximum tolerated of the treatment combination and to evaluate its safety and efficacy.
- Trial name
- NCT00463840
- Testing
- Oxaliplatin, 5FU, Radiation
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a…
- Trial name
- METRIC (NCT01997333)
- Testing
- CDX-011, Capecitabine
- Where
- 140 sites in United States, Australia and 7 more
- Volunteers
- 327 people
- Sponsor
- Celldex Therapeutics
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
This phase II trial studies how well giving bevacizumab, radiation therapy, and combination chemotherapy works in treating patients who are undergoing surgery for locally advanced nonmetastatic rectal cancer.
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Trial name
- NCT00321685
- Testing
- Bevacizumab, Capecitabine, Fluorouracil
- Where
- 107 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
- Trial name
- NCT04459715
- Testing
- Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT)
- Where
- 288 sites in United States, Argentina and 24 more
- Volunteers
- 730 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by…
- Conditions
- Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma
- Trial name
- NCT02302833
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Adrenocortical Carcinoma, Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- Spencer (NCT04187404)
- Testing
- EO2401, Nivolumab
- Where
- 12 sites in United States, Denmark and 6 more
- Volunteers
- 70 people
- Sponsor
- Enterome
Differentiated Thyroid Cancer (DTC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the…
- Trial name
- NCT04940052
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Cholangiocarcinoma
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
To assess the proposed therapy for patients with advanced gallbladder or biliary cancers.
- Trial name
- NCT01007552
- Testing
- Gemcitabine, Capecitabine and Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread from where it first…
- Conditions
- Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Trial name
- NCT04340843
- Testing
- Belinostat, Biopsy Procedure, Biospecimen Collection
- Where
- 39 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)